Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/21/2026 | Perform | Oppenheimer | |
| 11/18/2025 | $32.00 | Buy | BTIG Research |
| 3/31/2025 | $30.00 | Buy | BofA Securities |
| 3/31/2025 | $29.00 | Outperform | Wolfe Research |
| 3/31/2025 | $24.00 | Neutral | Goldman |
| 3/31/2025 | $28.00 | Buy | Stifel |
| 3/31/2025 | $28.00 | Overweight | Wells Fargo |
| 3/31/2025 | $27.00 | Overweight | Piper Sandler |
KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced that it has entered into a five-year term loan facility with funds managed by Pharmakon Advisors, LP. The non-dilutive financing consists of: $75 million tranche funded at closing, a portion of which was used to retire Kestra’s existing $45 million term loan and pay fees and expenses.$25 million tranche available at Kestra’s option through July 2027.$50 million tranche available at Kestra’s option through June 2028, subject to generating $150 million of trailing 12-months revenue.$50 million uncommitted tranc
KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2026. Financial Highlights Fiscal 4Q26 revenue of $28.6 million, an increase of 66% compared to the prior year period.FY26 revenue of $95.1 million, an increase of 59% compared to FY25.Fiscal 4Q26 gross margin of 54.8% compared to 44.3% in the prior year period.FY26 gross margin of 51.4% compared to 40.5% in FY25.FY27 revenue guidance of $137 million, an increase of 44% compared to fiscal year 2026. "Kestra concluded fiscal year 2026 wit
KIRKLAND, Wash., June 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report fourth quarter fiscal 2026 financial results after the market closes on Tuesday, July 14. Management will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. About KestraKestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitor
4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
4/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
Oppenheimer initiated coverage of Kestra Medical Technologies with a rating of Perform
BTIG Research initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $32.00
BofA Securities initiated coverage of Kestra Medical Technologies with a rating of Buy and set a new price target of $30.00
10-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
8-K - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Filer)
SCHEDULE 13G/A - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Subject)
4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
4 - KESTRA MEDICAL TECHNOLOGIES, LTD. (0001877184) (Issuer)
KIRKLAND, Wash., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Timothy Moran as Chief Business Officer, effective November 3. In this role, Mr. Moran will oversee business strategy, corporate business development, payor engagement and contracting, reimbursement strategy, and revenue cycle management. "I am pleased to welcome Tim as our Chief Business Officer," said Brian Webster, President and Chief Executive Officer of Kestra Medical Technologies. "With extensive expertise in cardiac and heart failure innovation, Tim is well positioned to join Kestra at this i
KIRKLAND, Wash., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a wearable medical device and digital healthcare company, today announced the appointment of Elizabeth Kwo, M.D. as an independent director to its board following her election at the company's annual general meeting of shareholders held earlier this month. "I am pleased to welcome Dr. Kwo to the Kestra board of directors," said Brian Webster, President and CEO of Kestra Medical Technologies. "As a physician, healthcare executive, and entrepreneur, she brings extensive experience building and scaling digital health platforms and advancing data-driven care models to improve patient outcomes.
MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His
KIRKLAND, Wash., July 14, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today reported financial results for the fourth quarter and fiscal year ended April 30, 2026. Financial Highlights Fiscal 4Q26 revenue of $28.6 million, an increase of 66% compared to the prior year period.FY26 revenue of $95.1 million, an increase of 59% compared to FY25.Fiscal 4Q26 gross margin of 54.8% compared to 44.3% in the prior year period.FY26 gross margin of 51.4% compared to 40.5% in FY25.FY27 revenue guidance of $137 million, an increase of 44% compared to fiscal year 2026. "Kestra concluded fiscal year 2026 wit
KIRKLAND, Wash., June 30, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, is scheduled to report fourth quarter fiscal 2026 financial results after the market closes on Tuesday, July 14. Management will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. About KestraKestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitor
KIRKLAND, Wash., March 03, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a leading wearable medical device and digital healthcare company, today announced that it will report third quarter fiscal 2026 financial results on Tuesday, March 17. Management will host a corresponding conference call at 4:30 p.m. Eastern Time. A live and archived webcast of the conference call will be available in the "Events" section of the investor relations website. Participants are encouraged to register on the website 10 minutes prior to the start of the conference call. About KestraKestra Medical Technologies, Ltd. is a leading wearable medical device and digital healthcare comp